1173694-01-3

Usage

Uses

Used in Pharmaceutical Research and Drug Discovery:
Ethyl 6-phenylH-imidazo[1,2-a]pyridine-2-carboxylate is employed as a chemical intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and potential biological activities make it a valuable asset in the development of new drugs, particularly those targeting viral and tumor-related diseases.
Used in Antiviral Applications:
In the field of antiviral research, ethyl 6-phenylH-imidazo[1,2-a]pyridine-2-carboxylate is used as a potential antiviral agent. Its specific molecular structure allows it to interact with viral components, potentially inhibiting viral replication and reducing the severity of viral infections.
Used in Antitumor Applications:
Ethyl 6-phenylH-imidazo[1,2-a]pyridine-2-carboxylate is also utilized in antitumor research, where it is investigated for its potential to inhibit the growth and proliferation of cancer cells. Its unique chemical properties may contribute to the development of novel therapeutic agents for the treatment of various types of cancer.
Used in Medicinal Chemistry Studies:
As a promising candidate for further exploration, ethyl 6-phenylH-imidazo[1,2-a]pyridine-2-carboxylate is used in medicinal chemistry studies to understand its interactions with biological targets and to optimize its structure for improved efficacy and safety.

Upstream product

• 214958-32-4 ethyl 6-iodo-1H-imidazo[1,2-a]pyridine-2-carboxylate 
• 98-80-6 phenylboronic acid 
• 67625-37-0 ethyl 6-bromoimidazo<1,2-a>pyridine-2-carboxylate 

Downstream Products

• 1173694-02-4 6-phenylimidazo[1,2-a]pyridine-2-carboxylic acid 

Relevant academic research and scientific papers

NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME

A compound selectively inhibiting Nav1.7 over Nav1.5 is provided. A heteroaromatic amide derivative or salt thereof showing high efficacy for various diseases associated with Nav1.7 such as pain, represented by the general formula (I) [wherein, X1-X2 is N-C or C-N, Y1 , Y2, Y3 and Y4 are -CH2-, -CR4aH- or -O- and so on, Z1 is-O- and so on, ring A is a 3- to 7-membered monocyclic aromatic ring and so on, R1a and R1b are a hydrogen atom or a halogen atom and so on, R2 is a hydrogen atom and so on, R3a, R3b and R3c are a hydrogen atom or an optionally substituted C1-C6 haloalkyl group and so on, R4a, R4b and R4c are, an optionally substituted C1-C6 haloalkyl group or C1-C6 haloalkoxy group and so on, R5a is a hydrogen atom and so on, R5a and R5b together form -CH2O- and so on, R6a and R6b are a hydrogen atom and so on, n is 1 or 2.].

NOVEL PHARMACEUTICAL COMPRISING HETEROAROMATIC AMIDE DERIVATIVE OR SALT THEREOF

PROBLEM TO BE SOLVED: To provide a compound useful for treating or preventing disease associated with voltage-dependent sodium channel (Nav1.7) such as disease involving a pain, disease involving an itch, autonomic nerve-associated disease, or a pharmaceutical composition thereof. SOLUTION: The present disclosure provides a compound illustrated by the following formula, and a pharmaceutical composition containing the same. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS

The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like.

Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions

Substituted tetrahydroimidazopyridine compounds corresponding to formula I: in which R1, R2 and R3 have defined meanings, processes for preparing such compounds, pharmaceutical compositions containing such compounds, and t